User:MaryGaulke/sandbox/Daiichi Sankyo requests

Hi! As noted above, I'm a COI editor representing Daiichi Sankyo (a client of my employer, Porter Novelli). I have some new requests for this article:


 * In the infobox, update
 * key_people   = Sunao Manabe (Representative Director, and President)

Ken Keller (President and CEO, Daiichi Sankyo, Inc.)
 * num_employees = 15,348 (as of March 2020)
 * to
 * key_people   = Sunao Manabe (Representative Director and CEO)

Hiroyuki Okuzawa (Representative Director, President and COO)

Ken Keller (President and CEO, Daiichi Sankyo, Inc.)
 * num_employees = 17,435 (as of May 2023)


 * In the infobox, update
 * revenue      = ▲ $ 9.028 billion USD (FY 2019) (¥  981.8 billion JPY) (FY 2019)
 * net_income   = ▲ $ 1.276 billion USD (FY 2019) (¥  138.8 billion JPY) (FY 2019)
 * to
 * revenue      = ▲ $ 9.44 billion USD (FY 2022) (¥  1,278 billion JPY) (FY 2022)
 * net_income   = ▲ $ 812 million USD (FY 2022) (¥  109.2 billion JPY) (FY 2022)


 * Update
 * It achieved JPY 981.8 billion in revenue in 2019. The company owns the American biotechnology company Plexxikon, American pharmaceutical company American Regent, German biotechnology company U3 Pharma, and recently sold Ranbaxy Laboratories in India.
 * to
 * It achieved JPY 1,278 billion in revenue in 2022. The company owns the American pharmaceutical company American Regent.
 * Plexxikon has been closed, and it seems odd to me to include the former Ranbaxy ownership in the lead.


 * Update
 * Daiichi Sankyo Co., Ltd. is the producer of Benicar (Olmesartan), an angiotensin II receptor antagonist and top selling drug in the U.S. Global sales of Olmesartan in 2013 were 300.2 billion yen.
 * to
 * Daiichi Sankyo invented and is developing Enhertu (trastuzumab deruxtecan), a HER2 directed antibody-drug conjugate (ADC) and the primary ADC in the company's oncology portfolio.
 * Daiichi Sankyo's patent on Benicar expired several years ago; Cosette Pharmaceuticals now holds US sales and distribution rights. I think Enhertu makes sense as the callout here given Daiichi Sankyo's current focus on oncology and Enhertu as a major product.


 * Move
 * The shutdown of Plexxikon was announced in 2022 as Daiichi Sankyo pivots to focus on more antibody-drug conjugate therapies.
 * from the end of the penultimate paragraph to the end of the third paragraph (the one about Plexxikon).


 * Delete
 * The transaction is set to close in December 2014, pending shareholder, court and regulatory approvals and other customary conditions.
 * This sentence is outdated and superseded by subsequent information.


 * In the sentence "On September 29, 2014, Daiichi Sankyo agreed to acquire Ambit Biosciences for approximately $410 million, the deal enabled Daiichi to gain the Phase III cancer compound quizartinib. ", delete "Phase III" – quizartinib is now approved for use in Japan and in the United States.
 * Update
 * Daiichi Sankyo developed Enhertu in cooperation with AstraZeneca,
 * to
 * Enhertu has been patented by Daiichi Sankyo and is being co-developed and co-commercialized in cooperation with AstraZeneca,
 * Per 's feedback above, noting I'm proposing Enhertu-related text for both the lead and Acquisitions section per MOS:LEADNOTUNIQUE, specifically the guideline that the information in the lead should generally also appear in the body of the article.


 * Add:
 * Ezharmia (valemetostat) (available only in Japan)


 * Update
 * Turalio (pexidartinib)
 * to
 * Turalio (pexidartinib) (available only in the United States)

Delete Since Daiichi Sankyo no longer holds the rights to Benicar.
 * Benicar (olmesartan medoxomil) (also sold as Benicar HCT, Azor, Olmetec, Rezaltas, Sevikar, and Tribenzor)


 * Delete
 * Valemetostat
 * Since it's now an oncology product, noted above.


 * Add
 * Ifinatamab deruxtecan (I-DXd; DS-7300)